Rohto Pharmaceutical Co (FRA:UC1) Total Payout Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UC1 Rohto Pharmaceutical Co Ltd FRA:UC1
73 GF Score
Price €15.20
GF Value €16.57
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Rohto Pharmaceutical Co Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Rohto Pharmaceutical Co's current Total Payout Ratio is .

Rohto Pharmaceutical Co Total Payout Ratio Related Terms

Rohto Pharmaceutical Co Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Rohto Pharmaceutical Co's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rohto Pharmaceutical Co Total Payout Ratio Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.18 0.18 0.39 0.27

Rohto Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:UC1 vs PG, CL, EL: Total Payout Ratio Comparison

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rohto Pharmaceutical Co Total Payout Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Total Payout Ratio falls into.


FRA:UC1
73GF Score
Rohto Pharmaceutical Co Ltd FRA:UC1
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rohto Pharmaceutical Co Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Rohto Pharmaceutical Co's Total Payout Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 0 + -53.055267525581) / 196.13955118913
=0.27

Rohto Pharmaceutical Co's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- ( + + ) / 57.490739391181
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Rohto Pharmaceutical Co (FRA:UC1) Overvalued in 2026?

Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued. The current stock price of €15.20 is trading 8.3% below its estimated GF Value™ of €16.57. GuruFocus considers Rohto Pharmaceutical Co to be Fairly Valued.

Key valuation signals for FRA:UC1:

  • Total Payout Ratio:
  • GF Value™: €16.57 vs. price of €15.20 (8.3% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the FRA:UC1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rohto Pharmaceutical Co Business Description

Other Exchanges RPHCF:USA4527:Japan
Address 1-8-1 Tatsuminishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co., Ltd. is a Japanese pharmaceutical and consumer healthcare company that develops, manufactures, and sells over-the-counter medicines and personal care products. Its core categories include eye care, such as eye drops and eyewashes; skin care, including dermatological medications, lip balms, sunscreens, and functional cosmetics; and oral medications, comprising gastrointestinal remedies, herbal medicines, and supplements. The company also produces in-vitro diagnostic reagents and other healthcare-related products. Rohto markets its brands to consumers through pharmacies, drugstores, and retail channels, supported by advertising and its well-known Rohto brand. Geographically, it operates through segments covering Japan, the Americas, Europe, and Asia, with Japan accounting for the majority of revenue. Its revenue model centers on product sales, supplemented by licensing and other healthcare-related activities.
73GF Score

Get the complete analysis for FRA:UC1

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.20
Price
€16.57
GF Value